Pend­ing FDA's OK, Te­va and Alvotech can bring their Ste­lara biosim­i­lar to US mar­ket by 2025

Alvotech and part­ner Te­va have now con­quered half the hur­dle in bring­ing a Ste­lara biosim­i­lar to mar­ket.

The two com­pa­nies an­nounced Mon­day that they agreed to a set­tle­ment and li­cense agree­ment with John­son & John­son to bring can­di­date AVT04 to US con­sumers by no lat­er than Feb. 21, 2025.

A Janssen rep­re­sen­ta­tive told End­points News in an email on Mon­day that the terms of the agree­ment are con­fi­den­tial, adding that the com­pa­ny “will con­tin­ue to de­fend the in­tel­lec­tu­al prop­er­ty as­so­ci­at­ed with our med­i­cines to pro­tect our abil­i­ty to in­no­vate and de­vel­op life-chang­ing ther­a­pies for pa­tients.”

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.